Mercredi, 8 Juillet 2020
Dernières nouvelles
Principale » Astrazeneca PLC (AZN) Earns "Buy" Rating from Sanford C. Bernstein

Astrazeneca PLC (AZN) Earns "Buy" Rating from Sanford C. Bernstein

24 Septembre 2017

On September 22 the stock rating was upgraded from " to "Outperform" in an announcement from Bernstein. Bank of America Corp DE now owns 45,744,976 shares of the company's stock valued at $1,424,498,000 after buying an additional 10,414,969 shares in the last quarter. Kepler Capital Markets reissued a "buy" rating and issued a GBX 5,200 ($70.11) price target on shares of AstraZeneca plc in a research note on Monday, September 11th. The stock has a market cap of $85.96 billion, a P/E ratio of 22.27 and a beta of 0.74. The average stock price target is $35.41 with 1 broker rating the stock a strong buy, 0 brokers rating the stock a buy, 3 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell. The short interest to Astrazeneca Plc's float is 0.57%.

It is trading at $33.84 significantly above the 50 day moving average which is $30.33 and which is just a bit higher than the 200 day moving average of $31.81.

The company is up from yesterday's close of 32.81. Bank of America Corp DE increased its stake in shares of Astrazeneca PLC by 29.5% during the first quarter. BlackRock Inc. now owns 6,910,657 shares of the company's stock valued at $215,198,000 after buying an additional 6,908,257 shares in the last quarter. Primecap Management Co. CA lifted its position in Astrazeneca PLC by 32.1% during the first quarter. Dorsey & Whitney Trust CO LLC raised its position in Astrazeneca PLC by 0.7% in the second quarter. Fisher Asset Management LLC now owns 11,081,856 shares of the company's stock worth $377,780,000 after purchasing an additional 9,160,764 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in Astrazeneca PLC by 7.9% in the 1st quarter. Astrazeneca PLC also was the target of some unusual options trading on Wednesday. The average volume of a stock suggests the liquidity of a particular company. This is an increase of 1,510% compared to the typical daily volume of 513 put options.

Versartis, Inc. (VSAR) Receives "Equal Weight" Rating from Morgan Stanley
The Company's products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. On September 22 the company was rated "Neutral" according to a Barclays report which is down from the previous " rating.

Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 27th. The dividend was $0.225 per share for the quarter which comes to $0.90 on an annualized basis. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & global copyright and trademark laws. On Wednesday, September 2 the stock rating was upgraded by HSBC to "Buy". Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. Institutional investors own 14.17% of the company's stock. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. The company had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. Astrazeneca PLC's revenue was down 9.9% compared to the same quarter a year ago. As of the latest earnings report the EPS was $1.52 and is expected to be $1.90 for the current year with 2,532,000,000 shares outstanding.

The business also recently disclosed a None dividend, which was paid on Monday, September 11th. Investors of record on Thursday, August 10th were paid a dividend of GBX 68.90 ($0.93) per share. This represents a yield of 2.98%. Astrazeneca PLC's payout ratio is now 44.92%.

Currently, EPS of AstraZeneca PLC (AZN) is 0.44 while the analysts predicted the EPS of the stock to be 0.42 suggesting the company fell short of the analysts' expectations. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The ex-dividend date was set for Wednesday the 9th of August 2017. The Firm focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Astrazeneca PLC (AZN) Earns